Abstract
Established infections with the human and simian immunodeficiency viruses (HIV and SIV, respectively) are thought to be permanent with even the most effective immune responses and antiretroviral therapies only able to control, but not clear, these infections1,2,3,4. Whether the residual virus that maintains these infections is vulnerable to clearance is a question of central importance to the future management of millions of HIV-infected individuals. We recently reported that approximately 50% of rhesus macaques (RM; Macaca mulatta) vaccinated with SIV protein-expressing rhesus cytomegalovirus (RhCMV/SIV) vectors manifest durable, aviraemic control of infection with the highly pathogenic strain SIVmac239 (ref. 5). Here we show that regardless of the route of challenge, RhCMV/SIV vector-elicited immune responses control SIVmac239 after demonstrable lymphatic and haematogenous viral dissemination, and that replication-competent SIV persists in several sites for weeks to months. Over time, however, protected RM lost signs of SIV infection, showing a consistent lack of measurable plasma- or tissue-associated virus using ultrasensitive assays, and a loss of T-cell reactivity to SIV determinants not in the vaccine. Extensive ultrasensitive quantitative PCR and quantitative PCR with reverse transcription analyses of tissues from RhCMV/SIV vector-protected RM necropsied 69–172 weeks after challenge did not detect SIV RNA or DNA sequences above background levels, and replication-competent SIV was not detected in these RM by extensive co-culture analysis of tissues or by adoptive transfer of 60 million haematolymphoid cells to naive RM. These data provide compelling evidence for progressive clearance of a pathogenic lentiviral infection, and suggest that some lentiviral reservoirs may be susceptible to the continuous effector memory T-cell-mediated immune surveillance elicited and maintained by cytomegalovirus vectors.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Maternal antibodies induced by a live attenuated vaccine protect neonatal mice from cytomegalovirus
npj Vaccines Open Access 03 February 2023
-
Alternative splicing and genetic variation of mhc-e: implications for rhesus cytomegalovirus-based vaccines
Communications Biology Open Access 19 December 2022
-
Neuroinflammatory transcriptional programs induced in rhesus pre-frontal cortex white matter during acute SHIV infection
Journal of Neuroinflammation Open Access 06 October 2022
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout



Change history
29 October 2014
A Correction to this paper has been published: https://doi.org/10.1038/nature13840
References
Chun, T. W. & Fauci, A. S. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 26, 1261–1268 (2012)
Lewin, S. R., Evans, V. A., Elliott, J. H., Spire, B. & Chomont, N. Finding a cure for HIV: will it ever be achievable? J. Int. AIDS Soc. 14, 4 (2011)
Deeks, S. G. & Walker, B. D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27, 406–416 (2007)
Picker, L. J., Hansen, S. G. & Lifson, J. D. New paradigms for HIV/AIDS vaccine development. Annu. Rev. Med. 63, 95–111 (2012)
Hansen, S. G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523–527 (2011)
Haase, A. T. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu. Rev. Med. 62, 127–139 (2011)
Lifson, J. D. et al. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J. Virol. 74, 2584–2593 (2000)
Sáez-Cirión, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013)
Hansen, S. G. et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nature Med. 15, 293–299 (2009)
Hansen, S. G. et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340, 1237874 (2013)
Ribeiro dos Santos, P. et al. Rapid dissemination of SIV follows multisite entry after rectal inoculation. PLoS ONE 6, e19493 (2011)
Deeks, S. G. et al. Towards an HIV cure: a global scientific strategy. Nature Rev. Immunol. 12, 607–614 (2012)
Burton, D. R. et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396–407 (2012)
Okoye, A. et al. Profound CD4+/CCR5+ T cell expansion is induced by CD8+ lymphocyte depletion but does not account for accelerated SIV pathogenesis. J. Exp. Med. 206, 1575–1588 (2009)
Shen, A. et al. Novel pathway for induction of latent virus from resting CD4+ T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J. Virol. 81, 1660–1670 (2007)
Loffredo, J. T. et al. Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J. Virol. 81, 8827–8832 (2007)
Tabb, B. et al. Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. J. Infect. Dis. 207, 880–892 (2013)
Cline, A. N., Bess, J. W., Piatak, M., Jr & Lifson, J. D. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34, 303–312 (2005)
Venneti, S. et al. Longitudinal in vivo positron emission tomography imaging of infected and activated brain macrophages in a macaque model of human immunodeficiency virus encephalitis correlates with central and peripheral markers of encephalitis and areas of synaptic degeneration. Am. J. Pathol. 172, 1603–1616 (2008)
Palmer, S. et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41, 4531–4536 (2003)
Keele, B. F. et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 206, 1117–1134 (2009)
Sacha, J. B. & Watkins, D. I. Synchronous infection of SIV and HIV in vitro for virology, immunology and vaccine-related studies. Nature Protocols 5, 239–246 (2010)
Montefiori, D. C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. Chapter 12, Unit 12.11. (2005)
Wolfe, D. A. & Hollander, M. Nonparametric Statistical Methods (Wiley, 1973)
Fisher, R. A. The logic of inductive inference. J. Roy. Stat. Soc. A 98, 39–54 (1935)
Agresti, A. & Coull, B. A. Approximate is better than “exact” for interval estimation of binomial proportions. Am. Stat. 52, 119–126 (1998)
Harrington, D. P. & Fleming, T. R. A class of rank test procedures for censored survival data. Biometrika 69, 553–566 (1982)
R Development Core Team. R, A Language and Environment for Statistical Computing; http://www.R-project.org (2011)
Acknowledgements
This work was supported by the AIDS Vaccine Research in Nonhuman Primates Consortium of the National Institute of Allergy and Infectious Diseases (NIAID; U19 AI095985), as well as other NIAID grants (RO1 AI060392, R37 AI054292, P01 AI094417 and U19 AI096109); the Bill & Melinda Gates Foundation-supported Collaboration for AIDS Vaccine Discovery (CAVD); the International AIDS Vaccine Initiative (IAVI) and its donors, particularly the US Agency for International Development (USAID); the National Center for Research Resources (P51 OD011092); and the National Cancer Institute (contract HHSN261200800001E). We thank A. Sylwester, A. Okoye, C. Kahl, S. Hagen, R. Lum, Y. Fukazawa, S. Shiigi and L. Boshears for technical or administrative assistance; C. Miller, N. Miller and T. Friedrich for provision of SIV stocks; K. Reimann for provision of the CD8-depleting monoclonal antibody; D. Watkins for MHC typing; D. Montefiori for neutralizing antibody assays; and A. Townsend for figure preparation. We acknowledge the contribution of M. A. Jarvis to the design, construction and initial in vitro characterization of all the strain 68.1-derived RhCMV vectors used in this study, including both previously published RhCMV/SIV vectors and a previously unpublished vector expressing an Mycobacterium tuberculosis Ag85B–ESAT6 fusion protein, used as a negative control in this study.
Author information
Authors and Affiliations
Contributions
S.G.H. planned and performed animal experiments, and analysed immunological and virological data, assisted by A.B.V., C.M.H., R.M.G., J.C.F., M.S.L., A.N.G., G.X. and N.W. M.P. and J.D.L. planned and performed SIV quantification, assisted by K.O., R.S. and Y.L. B.J.B. and J.B.S. performed infected cell recognition assays. B.F.K. performed sequencing analysis. J.D.E. performed immunohistological studies. S.L.P., J.M.T., A.W.L. and M.K.A. managed the animal protocols. J.A.N. and K.F. supervised CMV vector design and development. J.D.L. planned and supervised SIV quantification and immunohistological experiments. P.T.E. performed all statistical analyses. L.J.P. conceived the RhCMV vector strategy, supervised all experiments, analysed data, and wrote the paper, assisted by S.G.H., J.D.L. and J.B.S.
Corresponding authors
Ethics declarations
Competing interests
Oregon Health & Science University, and authors L.J.P., S.G.H., K.F. and J.A.N. have a considerable financial interest in TomegaVax, Inc., a company that may have a commercial interest in the results of this research and technology. The potential individual and institutional conflicts of interest have been reviewed and managed by Oregon Health & Science University.
Supplementary information
Supplementary Information
This file contains Supplementary Figures 1-22, Supplementary Tables 1-3 and additional references. (PDF 2610 kb)
Rights and permissions
About this article
Cite this article
Hansen, S., Jr, M., Ventura, A. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104 (2013). https://doi.org/10.1038/nature12519
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature12519
This article is cited by
-
Maternal antibodies induced by a live attenuated vaccine protect neonatal mice from cytomegalovirus
npj Vaccines (2023)
-
Neuroinflammatory transcriptional programs induced in rhesus pre-frontal cortex white matter during acute SHIV infection
Journal of Neuroinflammation (2022)
-
Alternative splicing and genetic variation of mhc-e: implications for rhesus cytomegalovirus-based vaccines
Communications Biology (2022)
-
Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus
Nature Communications (2022)
-
Development of a reverse transcription droplet digital PCR (RT-ddPCR) assay for sensitive detection of simian immunodeficiency virus (SIV)
Virology Journal (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.